Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.